# Neuron23

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuron23

- Industry: Pharmaceuticals
- Headquarters: South San Francisco, US
- Website: www.neuron23.com
- Total disclosed funding: $310M
- Latest round: Series D (Jun 24, 2025)
- Investors on record: 10

## About

Founded in 2018 and headquartered in San Francisco, US, Neuron23, Inc. is a biotechnology company dedicated to developing precision medicines using advanced data science and genetic insights to combat severe diseases, specializes in precision medicine and innovative drug discovery. In June 2025, Neuron23, Inc. raised USD 96.5 million in series B funding led by an unspecified investor, with participation from returning investors Acorn Bioventures, HBM Partners, Kleiner Perkins, Blue Owl Capital, Redmile Group, SB Investment Advisers, and Westlake Village BioPartners. The company was co-founded by Adam Knight, Beth Seidenberg, and Michael Almstetter, while Nancy Stagliano serves as CEO.Neuron23 is focused on developing precision medicines that harness the synergy of cutting-edge data science and human genetics to address debilitating diseases. Employing an innovative AI-based drug discovery model, they aim to identify novel molecular targets leading to effective treatments tailored to individual patient needs. Their product pipeline includes NEU-411, a brain-penetrant LRRK2 inhibitor, and NEU-111, a TYK2 inhibitor designed for treating neuroimmunological conditions, targeting healthcare providers and pharmaceutical partners primarily in the U.S. market. Neuron23 generates revenue through strategic partnerships and collaborations with biopharmaceutical companies and research institutions. Their business structure is primarily B2B, focusing on licensing agreements and research partnerships that share development costs and risks. The company's flagship products, such as NEU-411 and NEU-111, follow an innovative pricing framework aligned with the advanced nature of their precision medicine solutions, including milestone payments tied to clinical trial achievements and royalties from product sales, supporting ongoing research efforts while ensuring financial sustainability.With the recent Series C funding of USD 100 mn raised in November 2021, Neuron23, Inc. plans to invest in its lead programs targeting LRRK2 and TYK2 to address Parkinson's disease and systemic inflammatory conditions. The funding will also enhance their clinical development team, precision neuroimmunology platform, and data sciences capabilities. The company aims to expand its product offerings and may target global markets as their solutions mature.

## Funding rounds

- Series D, Jun 24, 2025, $97M — Kleiner Perkins, HBM Partners, Redmile Group, SB Investment Advisers, Westlake Village BioPartners, Acorn Bioventures, Blue Owl
- Series C, Nov 11, 2021, $100M — Kleiner Perkins, HBM Partners, Redmile Group, Cowen Investment Management, Perceptive Advisors, SB Investment Advisers, Surveyor Capital, Westlake Village BioPartners, Acorn Bioventures
- Series A, Dec 16, 2020, $34M — Kleiner Perkins, Westlake Village BioPartners
- Series B, Oct 16, 2020, $80M — Kleiner Perkins, HBM Partners, Redmile Group, Cowen Investment Management, Perceptive Advisors, Surveyor Capital, Westlake Village BioPartners, Acorn Bioventures

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series B, Series A, Series C, Series D
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B, Series C, Series D
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B, Series C, Series D
- Cowen Investment Management — Series B, Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B, Series C
- Surveyor Capital — Series B, Series C
- Westlake Village BioPartners (https://capitalatlas.ai/funds/westlake-village-biopartners) — Series B, Series A, Series C, Series D
- Acorn Bioventures (https://capitalatlas.ai/funds/acorn-bioventures) — Series B, Series C, Series D
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series C, Series D
- Blue Owl (https://capitalatlas.ai/funds/blue-owl) — Series D